Bohlok A, et al. - Given that for locally advanced rectal cancer (LARC), recommended treatment includes neoadjuvant chemoradiotherapy (NACRT) followed by surgery and total mesorectal excision (TME), researchers evaluated if assessment of Dworak’s tumor regression grade (TRG) after NACRT had the potential to select patients who may benefit from adjuvant chemotherapy (ACT). From the Bordet Institute database, data for patients who underwent NACRT and TME for LARC between 2007 and 2014 were retrieved. Researchers reported that TRG was a prognostic factor for both overall survival and disease-free survival, but did not seem to have a significant value for choosing subjects with LARC treated with NACRT who could benefit from ACT.